General Updates | Factors to consider when approaching R/R multiple myeloma
Ezzat El Hassadi
• 20 Oct 2022
Ezzat El Hassadi, MD, University Hospital Waterford, Waterford, Ireland, explains the key components considered when approaching the treatment of relapsed/refractory (R/R) multiple myeloma, including patient characteristics, disease biology, and treatment toxicity. Dr El Hassadi highlights the importance of considering a patient’s prior exposure to therapies, and discusses the use of daratumumab, triplet therapy, and transplantation in this setting. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
